80 related articles for article (PubMed ID: 2449616)
1. Abuse liability assessment of buprenorphine-naloxone combinations.
Bigelow GE; Preston KL; Liebson IA
NIDA Res Monogr; 1987; 76():145-9. PubMed ID: 2449616
[No Abstract] [Full Text] [Related]
2. Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
Preston KL; Bigelow GE; Liebson IA
Psychopharmacology (Berl); 1988; 94(4):484-90. PubMed ID: 2453895
[TBL] [Abstract][Full Text] [Related]
3. Intravenous hydromorphone: effects in opiate-free and methadone maintenance subjects.
McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
NIDA Res Monogr; 1983 Apr; 43():238-44. PubMed ID: 6192340
[No Abstract] [Full Text] [Related]
4. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
Preston KL; Bigelow GE; Liebson IA
NIDA Res Monogr; 1987; 76():157-61. PubMed ID: 2449617
[No Abstract] [Full Text] [Related]
5. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
6. The effects of buprenorphine in methadone-dependent volunteers.
Strain EC; Bigelow GE; Preston KL; Liebson I
NIDA Res Monogr; 1990; 105():584. PubMed ID: 1715035
[No Abstract] [Full Text] [Related]
7. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
8. Physiological and subjective effects of hydromorphone in postaddict volunteers.
McCaul M; Stitzer M; Bigelow G; Liebson I
NIDA Res Monogr; 1982 Apr; 41():301-8. PubMed ID: 6181412
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine alone and in combination with naloxone in non-dependent humans.
Weinhold LL; Preston KL; Farre M; Liebson IA; Bigelow GE
Drug Alcohol Depend; 1992 Aug; 30(3):263-74. PubMed ID: 1396108
[TBL] [Abstract][Full Text] [Related]
11. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
12. Sublingual versus subcutaneous buprenorphine in opiate abusers.
Jasinski DR; Fudala PJ; Johnson RE
Clin Pharmacol Ther; 1989 May; 45(5):513-9. PubMed ID: 2721107
[TBL] [Abstract][Full Text] [Related]
13. Subjective and physiologic effects of intravenous buprenorphine in humans.
Pickworth WB; Johnson RE; Holicky BA; Cone EJ
Clin Pharmacol Ther; 1993 May; 53(5):570-6. PubMed ID: 8491067
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
[TBL] [Abstract][Full Text] [Related]
15. Naloxone response in non-dependent man: effect on six physiological variables.
Zilm DH
Neuropharmacology; 1980 Jul; 19(7):591-5. PubMed ID: 7402449
[No Abstract] [Full Text] [Related]
16. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
Jones HE; Bigelow GE; Preston KL
J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
[TBL] [Abstract][Full Text] [Related]
17. Naloxone and levallorphan: a comparative study of agonist activity.
Evans JM; Hogg MI; Lunn JN; Rosen M
Br J Anaesth; 1973 Jun; 45(6):642. PubMed ID: 4718261
[No Abstract] [Full Text] [Related]
18. The implementation of buprenorphine/naloxone in college health practice.
DeMaria PA; Patkar AA
J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine and naloxone interactions in methadone maintenance patients.
Mendelson J; Jones RT; Welm S; Brown J; Batki SL
Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers.
Walsh SL; Gilson SF; Jasinski DR; Stapleton JM; Phillips RL; Dannals RF; Schmidt J; Preston KL; Grayson R; Bigelow GE
Neuropsychopharmacology; 1994 May; 10(3):157-70. PubMed ID: 7916913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
